Simtomax® has obtained TGA registration, allowing for commercialization in Australia

4 May 2014

Augurix and HealthScreenSolutions Pty Ltd are pleased to announce that Simtomax®, a rapid point-of-care diagnostic test for celiac disease, has been registered by the Australian Therapeutics Goods Administration (TGA).

Augurix and HealthScreenSolutions had entered into a commercialization agreement for Simtomax®, providing HealthScreenSolutions with the exclusive right to distribute and supply Simtomax® in Australia and New Zealand.

Get the PressRelease


Augurix raises CHF 3 million to further develop program on Celiac and Crohn's Disease

27 Jan 2014

Augurix SA (“Augurix”), announced today it has successfully completed a round of financing by raising CHF 3 million from private investors.

The successful financing of CHF 3 million was fully subscribed by new private investors. The company will call on these funds in two tranches according to its financial requirements. The new funds, along with existing cash resources, will enable Augurix to expand the marketing of its products, and further advance its clinical and pre-clinical medical diagnostic devices pipeline. These resources will mainly support the regulatory submission in the USA of Simtomax®, a rapid test for the early screening of Celiac Disease, and support the development of a program aiming at developing a new oral contrast agent dedicated to the early stratification of patients suffering from pre-fibrotic Inflammatory Bowel Diseases (IBD).

Get the press release

Augurix was proud sponsor of ICDS 2013, the 15th International Celiac Disease Symposium - Chicago, USA

1 Aug 2013

Augurix Diagnostics announced sponsorship and participation to the 15th International Celiac Disease Symposium, that took place on September 22-25 2013 in Chicago. ICDS is a global scientific conference for everyone who is interested in the study, treatment, and management of celiac disease and gluten-related disorders.

At Augurix, we are in the business of screening, diagnosing and monitoring one of the most under-diagnosed medical conditions worldwide: Celiac Disease. So ICDS is a bit our conference, and we presented our rapid screening test Simtomax®, with its latest development.

The scientific communications presented clinical results on using Simtomax®:

  • Evaluation of a rapid test for celiac disease screening in a pediatric population
    Claude-Olivier Marti, Benoit Fellay et al.
  • Diagnostic accuracy of a new point-of-care screening assay for celiac disease
    Faiza Benkebil, Christophe Combescure et al.
  • Celiac Disease and IgA deficiency: Evaluation of a Point of Care Test based on detection of antibodies against deamidated gliadin peptides
    Françoise Bienvenu, Lorna Garnier et al.

We were present on booth 501. We introduced Simtomax® to several visitors, and provided them with all necessary information for using the test in their practice, hospital, laboratory, pharmacy or screening center.